KRYS as reported
Krystal Biotech, Inc. reported $440M of revenue over the trailing twelve months, +23% on the year before. 9 reported series are charted on this page, each one as filed.
$440M
Revenue, trailing twelve months · to Q2 2026 · +23% against the twelve months before
- Net Income
- $241M
Net Income · +65% year on year · trailing twelve months to Q2 2026
- Free Cash Flow
- $258M
Free Cash Flow · +39% year on year · trailing twelve months to Q2 2026
- Op Margin
- 45%
Op Margin · trailing twelve months to Q2 2026
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Revenue | $440M | +23% | Q2 2026 |
| Net Income | $241M | +65% | Q2 2026 |
| EPS | $7.98 | +62% | Q2 2026 |
| Op Margin | 45% | n/a | Q2 2026 |
| Net Margin | 56% | n/a | Q2 2026 |
| ROE | 17% | n/a | Q2 2026 |
| ROA | 16% | n/a | Q2 2026 |
| Free Cash Flow | $258M | +39% | Q2 2026 |
| P/E | 45.1 | n/a | today |
Every figure straight from the statements as filed with the SEC, no scoring, no adjustment. Open a series for its full history.
Krystal Biotech, Inc. (KRYS) - Revenue & ProfitRevenue & ProfitKrystal Biotech, Inc. (KRYS)
Revenue (TTM)Net Income (TTM)
Powered byryufin.com